- Home
- EWTX vs DGII Comparison
EWTX vs DGII Comparison
Compare EWTX & DGII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWTX
- DGII
- Stock Information
- Founded
- EWTX 2017
- DGII 1985
- Country
- EWTX United States
- DGII United States
- Employees
- EWTX N/A
- DGII N/A
- Industry
- EWTX Biotechnology: Pharmaceutical Preparations
- DGII Computer peripheral equipment
- Sector
- EWTX Health Care
- DGII Technology
- Exchange
- EWTX Nasdaq
- DGII Nasdaq
- Market Cap
- EWTX 1.5B
- DGII 1.3B
- IPO Year
- EWTX 2021
- DGII N/A
- Fundamental
- Price
- EWTX $14.06
- DGII $35.92
- Analyst Decision
- EWTX Buy
- DGII Buy
- Analyst Count
- EWTX 9
- DGII 4
- Target Price
- EWTX $39.89
- DGII $38.75
- AVG Volume (30 Days)
- EWTX 804.3K
- DGII 198.6K
- Earning Date
- EWTX 11-06-2025
- DGII 11-12-2025
- Dividend Yield
- EWTX N/A
- DGII N/A
- EPS Growth
- EWTX N/A
- DGII 147.46
- EPS
- EWTX N/A
- DGII 1.14
- Revenue
- EWTX N/A
- DGII $420,935,000.00
- Revenue This Year
- EWTX N/A
- DGII $2.46
- Revenue Next Year
- EWTX N/A
- DGII $7.77
- P/E Ratio
- EWTX N/A
- DGII $31.36
- Revenue Growth
- EWTX N/A
- DGII N/A
- 52 Week Low
- EWTX $10.60
- DGII $22.39
- 52 Week High
- EWTX $38.12
- DGII $37.07
- Technical
- Relative Strength Index (RSI)
- EWTX 46.82
- DGII 59.54
- Support Level
- EWTX $13.69
- DGII $33.74
- Resistance Level
- EWTX $15.16
- DGII $36.94
- Average True Range (ATR)
- EWTX 0.68
- DGII 1.04
- MACD
- EWTX -0.11
- DGII 0.17
- Stochastic Oscillator
- EWTX 17.81
- DGII 71.10
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
About DGII Digi International Inc.
Digi International Inc is a Minnesota corporation. The company provides business and mission-critical and Internet of Things (IoT) connectivity products and services. It has two segments: IoT Products and Services and IoT Solutions. The IoT Products and Services segment consists of distinct communications products and communication product development services. IoT Solutions segment offers wireless temperature and other environmental condition monitoring services as well as employee task management services. The company generates majority of its revenue from the IoT Products & Services segment. Geographically, the company generates majority of its revenue from its business in the United States and also has its presence in Europe, Middle East and Africa and Rest of the world.